AZNCF News and Press, AstraZeneca Plc From 11/12/23

2023-11-12 01:45:00 ET Summary Eccogene out-licenses global rights for its GLP-1 agonist to AstraZeneca in a $2 billion deal. Biotheus sells ex-China rights for a bispecific antibody candidate to BioNTech for $55 million upfront. WuXi XDC conducts a $500 million Hong Kong IPO ...

2023-11-09 17:22:09 ET AstraZeneca PLC (AZN) Q3 2023 Earnings Conference Call November 9, 2023 9:00 am ET Corporate Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Chief Executive Officer Aradhana Sarin - Chief Financial Officer David Fre...

2023-11-09 02:19:24 ET More on AstraZeneca AstraZeneca: Revenue Softening Possible, Profits To Rise AstraZeneca: Buy This Blue-Chip Bargain For A Richer Retirement AstraZeneca: Hidden Gem Of The Pharma Sector Is A Great Buy Opportunity Earnings week ahead: Di...

2023-11-08 17:56:47 ET Summary BlackRock Enhanced International Dividend Trust provides exposure to international equities, with a focus on dividend-paying companies. BGY offers a discounted share price and is invested in discounted international markets, making it an appealing op...

2023-11-08 14:17:32 ET Summary AstraZeneca's upcoming results have the potential of turning around its 8% price decline YTD as profit growth can be sustained, making its forward multiples attractive again. The outlook on revenues is less buoyant, on the expected decline in sales o...

2023-11-07 17:07:59 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2023-11-04 11:35:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund declined 6.98% in Q3 2023, underperforming the benchma...

2023-11-03 18:57:50 ET Summary Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. The company recently entered into a collaboration...

2023-11-02 09:00:00 ET Summary Pfizer's stock has dropped due to a decline in revenues post-COVID, presenting a value investment opportunity. The company still generates significant gross profit and has a strong revenue growth rate. Pfizer's low Price-to-Earnings ratio and imp...

2023-10-26 10:53:55 ET More on BioNTech, GSK, etc. Pfizer: Ignore The Noise And Buy This Deep Value Seagen's Acquisition: EU Approval And Potential Upside Pfizer: Huge Upside Potential And 5%+ Yield Pfizer, BioNTech post early-stage data for COVID-flu combo s...